Previous 10 | Next 10 |
After staging a rally from the start of 2019, Vertex ( VRTX ) has experienced some price setback as a result of a cut in the revenue forecasts from analysts, as pushback against pricing of its products in the UK and EU rage on. Here is the outlook for VRTX as we head towards the start of the s...
Thinly traded micro cap Eloxx Pharmaceuticals ( ELOX +1.7% ) is up on below-average volume on the heels of encouraging preclinical data on lead candidate ELX-02 in cystic fibrosis (CF). The results were presented at the ECFS Basic Science Conference in Croatia. More news on: Eloxx Phar...
Aldeyra Therapeutics (NASDAQ: ALDX ) +59% on positive reproxalap data . More news on: Aldeyra Therapeutics, Inc., Hunter Maritime Acquisition Corp., Bed Bath & Beyond Inc., Stocks on the move, Read more ...
Proteostasis Therapeutics (NASDAQ: PTI ) -56% on disappointing data on CF candidates. More news on: Proteostasis Therapeutics, Inc., Recro Pharma, Inc., Motif Bio plc, Stocks on the move, Read more ...
Proteostasis Therapeutics (NASDAQ: PTI ) slumps 48% premarket on increased volume on the heels of its announcement of Phase 1 data on cystic fibrosis (CF) triplet therapy of PTI-801 (CFTR corrector), PTI-808 (CFTR potentiator) and PTI-428 (CFTR amplifier) and separate studies o...
BOSTON , March 25, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein pro...
BOSTON , March 7, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein ...
BOSTON , Feb. 27, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein ...
BOSTON , Feb. 20, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processi...
HENDERSON, NV / ACCESSWIRE / February 12, 2019 / Below are several companies in the biotech space that are making news and drawing investor interest. These companies have the potential to make investors serious profits. An oversold biotech with potential we really like is Delcath Systems,...
News, Short Squeeze, Breakout and More Instantly...
Yumanity Therapeutics Inc Com Company Name:
PTI Stock Symbol:
NASDAQ Market:
Brawijaya University develops GIS-based IoT for disaster mitigation Malang, East Java, Indonesia, Sept 30, 2022 - (ACN Newswire) - Brawijaya University has developed an Internet of Things (IoT) technology based on the Geographic Information System (GIS) to mitigate disasters i...
Proteostasis Therapeutics, Inc. Stockholders Approve Business Combination with Yumanity Therapeutics, Inc.; Board Sets Reverse Stock Split Ratio PR Newswire BOSTON , Dec. 22, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. ("Proteostasis") (Nasdaq: PTI)...
Leading institutional investors commit $33.6 million through a common stock private investment in public equity (“PIPE”) led by Fidelity Management & Research Company, LLC and Invus Proteostasis plans to adjourn its special meeting of stockholders to December 2...